Strategic Collaboration Recent partnership with Coegin Pharma and Lund University to leverage X-ray crystallography for drug candidates indicates a growing emphasis on collaborative discovery programs and external customer engagements. Sales opportunities include joint projects for structure-based drug design, fragment screening services, and biosimilar comparability studies with academic and biotech partners.

Integrated Service Stack SARomics offers a full spectrum from protein crystallography and NMR to computational chemistry and fragment screening, plus proprietary WAC technology. This enables cross-sell to customers needing end-to-end structure-guided discovery and rapid hit-to-lead workflows, particularly for early-stage programs seeking diverse screening modalities.

Proximity Advantage Location at Medicon Village in Lund near MAX IV enhances access to world-class synchrotron facilities, potentially shortening project timelines and increasing throughput. Use this to position faster delivery, pilot studies, and on-site collaboration options as differentiators in bids.

Biosimilar & HOS Expertise Experience in antibody–antigen complex crystallography and higher-order structure comparability analyses for biosimilars positions SARomics to win work in biosimilar testing, HOS verification, and regulatory-focused structure studies for third-party manufacturers and biotech developers.

Growth Potential Current revenue under $1M with a focused team of 11–50 employees suggests scalable opportunities through expanding service capacity, tiered service offerings (standard vs Premium), and expanding library of off-the-shelf structures to attract new customers in biotech and pharma seeking rapid structure solutions.